Cited by 697Statistical Methods in Clinical TrialsEthics in Clinical ResearchPharmaceutical industry and healthcare

The DOI matches its Crossref record.

Phase II and Phase III attrition rates 2011–2012

Arrowsmith, John, Miller, Philip·2013·Nature Reviews Drug Discovery

DOI 10.1038/nrd4090

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nrd4090

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 697

Characterization and applications of chimeric mice with humanized livers for preclinical drug development
Tateno, C., & Kojima, Y. (2020) · Laboratory Animal Research · doi:10.1186/s42826-019-0032-y · Cited by 36
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“6,7 Especially, the cardiovascular drug development appears to be in a drought.”
Background
Can you trust your animal study data?
Peers, I. S., South, M. C., Ceuppens, P. R., Bright, J. D., & Pilling, E. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090-c1 · Cited by 35
Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial
Saxena, D., Spino, M., Tricta, F., Connelly, J., Cracchiolo, B. M., Hanauske, A.-R., Gandolfi, D. D., Mathews, M. B., Karn, J., Holland, B. K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154842 · Cited by 37
“Furthermore, preclinical models for novel effects and targets are unreliable predictors for achievable biological impact and have been implicated in the high attrition rate of clinical trials [47,48].”
Background
3D Scaffolds to Model the Hematopoietic Stem Cell Niche: Applications and Perspectives
Congrains, A., Bianco, J., Rosa, R. G., Mancuso, R. I., & Saad, S. T. O. (2021) · Materials · doi:10.3390/ma14030569 · Cited by 40
Statistical Innovations in Cancer Research
Lee, J. J., & Berry, D. A. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm020 · Cited by 35
IUPHAR review: Navigating the role of preclinical models in pain research
Karimi, S. A., Zahra, F. T., & Martin, L. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107073 · Cited by 36
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 41
“98,99 On the basis of an analysis of data between the years 2009 and 2018, it was estimated that the median investment in research and development required to bring a new drug to market amounts to $1,142 million, 100 yet the low success rates translate into substantial social costs amounting to…”
In Vitro 3D Modeling of Neurodegenerative Diseases
Louit, A., Galbraith, T., & Berthod, F. (2023) · Bioengineering · doi:10.3390/bioengineering10010093 · Cited by 37
“However, technical and ethical limits appear, as well as a doubt concerning the reliability of transposing these results to humans [4,5].”
Progress in developing microphysiological systems for biological product assessment
Mansouri, M., Lam, J., & Sung, K. E. (2024) · Lab on a Chip · doi:10.1039/d3lc00876b · Cited by 38
Dynamic microphysiological system chip platform for high-throughput, customizable, and multi-dimensional drug screening
Zhu, Y., Jiang, D., Qiu, Y. L., Liu, X., Bian, Y., Tian, S., Wang, X., Hsia, K. J., Wan, H., Zhuang, L., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.019 · Cited by 35
“However, many drugs fail in clinical trials due to efficacy and safety issues [1].”
Background
Advanced Microengineered Lung Models for Translational Drug Discovery
Niemeyer, B. F., Zhao, P., Tuder, R. M., & Benam, K. H. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218760217 · Cited by 33
CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson, P. H., Clark, J. A., & Cross, A. J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104624 · Cited by 35
Culturing substrates influence the morphological, mechanical and biochemical features of lung adenocarcinoma cells cultured in 2D or 3D
Prina‐Mello, A., Jain, N., Liu, B., Kilpatrick, J. I., Tutty, M. A., Bell, A. P., Jarvis, S., Volkov, Y., & Movia, D. (2017) · Tissue and Cell · doi:10.1016/j.tice.2017.11.003 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Identifying active ingredients in cognitive-behavioral therapies: What if we didn't?Preprint
Lorenzo‐Luaces, L. (2022) · Behaviour Research and Therapy · doi:10.1016/j.brat.2023.104365 · Cited by 33
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges
Cummings, J. L., & Zhong, K. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.884923 · Cited by 32
“Across therapeutic areas, 59% of Phase II compounds and 52% of Phase III compounds fail for lack of efficacy [6].”
Background
Refining Early Antitumoral Drug Development
Ocaña, A., García‐Alonso, S., Amir, E., & Pandiella, A. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.09.003 · Cited by 31
Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening
Ovics, P., Regev, D., Baskin, P., Davidor, M., Shemer, Y., Neeman-Egozi, S., Ben‐Haim, Y., & Binah, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197320 · Cited by 31
Protections for clinical trials in low and middle income countries need strengthening not weakening
Dal‐Ré, R., Ndebele, P., Higgs, E. S., Sewankambo, N. K., & Wendler, D. S. (2014) · BMJ · doi:10.1136/bmj.g4254 · Cited by 33
Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy
Silva, M., Martins, D., Charrua, A., Piscitelli, F., Tavares, I., Morgado, C., & Marzo, V. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.007 · Cited by 31
Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
Fuh, F. K., Looney, C., Li, D., Poon, K. A., Dere, R. C., Danilenko, D. M., McBride, J., Reed, C., Chung, S., Zheng, B., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13697 · Cited by 30
“The successful progression of therapeutics from Phase III clinical studies to marketing approval has decreased to only ~50% in recent years (Arrowsmith, 2011; Arrowsmith and Miller, 2013).”
Background
Designer bacteria as intratumoural enzyme biofactories
Lehouritis, P., Hogan, G. E., & Tangney, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.012 · Cited by 31
“The defining reason for failure of oncological medicines in late-stage clinical trials is a lack of therapeutic efficacy [139].”
Background
Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids
Zietek, T., Boomgaarden, W., & Rath, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081280 · Cited by 33
A guide to open science practices for animal research
Diederich, K., Schmitt, K. D., Schwedhelm, P., Bert, B., & Heinl, C. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001810 · Cited by 32
Recommendations toward a human pathway-based approach to disease research
Marshall, L. J., Austin, C. P., Casey, W., Fitzpatrick, S. C., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.038 · Cited by 28
Phenotypic Screening and Fragment-Based Approaches to the Discovery of Small-Molecule Bromodomain Ligands
Jennings, L. E., Measures, A. R., Wilson, B. G., & Conway, S. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.197 · Cited by 29
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Göttlich, C., Müller, L. C., Kunz, M., Schmitt, F., Walles, H., Walles, T., Dandekar, T., Dandekar, G., & Nietzer, S. (2016) · Journal of Visualized Experiments · doi:10.3791/53885 · Cited by 29
In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs
Campbell, B. R., Trotter, D. E. G., Hines, C. D. G., Li, W., Patel, M. R., Zhang, W., & Evelhoch, J. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw019 · Cited by 32
“The main reasons for attrition are safety and lack of efficacy, which respectively accounted for 28% and 56% of molecules failing in Phase 2 or Phase 3 from 2011 to 2012 (Arrowsmith and Miller 2013).”
Background
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 32
Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma
Sukei, T., Palma, E., & Urbani, L. (2021) · Cancers · doi:10.3390/cancers13215586 · Cited by 29
Towards integrative systems pharmacology models in oncology drug development
van Hasselt, J. G. C., & van der Graaf, P. H. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.06.004 · Cited by 34
Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations
Gustafsson, S. S., Eriksson, J., Syvänen, S., Eriksson, O., Hammarlund‐Udenaes, M., & Antoni, G. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.04.068 · Cited by 29
Clinical Implementation of Precision Medicine in Gastric Cancer
Jeon, J., & Cheong, J. (2019) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2019.19.e25 · Cited by 31
“Therefore, there is a need for novel preclinical models for GC [36-38].”
Background
The breathtaking world of human respiratory in vitro models: Investigating lung diseases and infections in 3D models, organoids, and lung‐on‐chip
Dichtl, S., Posch, W., & Wilflingseder, D. (2024) · European Journal of Immunology · doi:10.1002/eji.202250356 · Cited by 31
3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns
Mallya, D., Gadre, M. A., Varadharajan, S., & Vasanthan, K. S. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1457872 · Cited by 33
Identifying Protein Features Responsible for Improved Drug Repurposing Accuracies Using the CANDO Platform: Implications for Drug Design
Mangione, W., & Samudrala, R. (2019) · Molecules · doi:10.3390/molecules24010167 · Cited by 25
Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets
Rouillard, A. D., Hurle, M. R., & Agarwal, P. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006142 · Cited by 27
A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates
Wang, D. Y. Q., Hensman, J. J., Kutkaite, G., Toh, T. S., Galhoz, A., GDSC Screening Team, Lightfoot, H. W., Yang, W., Soleimani, M., Barthorpe, S., et al. (2020) · eLife · doi:10.7554/elife.60352 · Cited by 28
Bioinspired human stomach-on-a-chip with in vivo like function and architecture
Ferreira, D. A., Conde, J. P., Rothbauer, M., Ertl, P., Granja, P. L., & Oliveíra, C. (2023) · Lab on a Chip · doi:10.1039/d2lc01132h · Cited by 28
An AI/ML-Based Strategy for Disaster Response and Evacuation of Victims in Aged Care Facilities in the Hawkesbury-Nepean Valley: A Perspective
Munawar, H. S., Mojtahedi, M., Hammad, A. W. A., Ostwald, M. J., & Waller, S. T. (2022) · Buildings · doi:10.3390/buildings12010080 · Cited by 29
Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine
Grixti, J. M., O’Hagan, S., Day, P. J., & Kell, D. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00155 · Cited by 27
“Nowadays attrition occurs largely for reasons of toxicity or lack of efficacy (Kola and Landis, 2004; Arrowsmith and Miller, 2013), and runs in excess of 90% (e.g., Kola and Landis, 2004; Kell, 2013, and see for full details http://csdd.tufts.edu/files/uploads/Tufts_CSDD_…”
Background
Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology
Taylor, D. L., Gough, A., Schurdak, M. E., Vernetti, L. A., Chennubhotla, C. S., Lefever, D. E., Pei, F., Faeder, J. R., Lezon, T. R., Stern, A. M., et al. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_239 · Cited by 28
“80% for those new drug candidates that enter phase 2 clinical trials (Arrowsmith and Miller 2013), although in recent years there has been some improvement concurrent with an increase in the percentage of biologics and a more critical triage of candidates (Smietana et al.”
BackgroundInfluential
Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response
Saygılı, E., Yıldız-Ozturk, E., Green, M. J., Ghaemmaghami, A. M., & Yeşil-Çeliktaş, Ö. (2021) · Biomicrofluidics · doi:10.1063/5.0038924 · Cited by 27
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid
Dickinson, P. A., Kesisoglou, F., Flanagan, T. R., Martinez, M. N., Mistry, H. B., Crison, J. R., Polli, J. E., Cruañes, M. T., Serajuddin, A. T. M., Müllertz, A., et al. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.07.024 · Cited by 27
Advances in Predictive Toxicology for Discovery Safety through High Content Screening
Persson, M., & Hornberg, J. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00248 · Cited by 26
Novel test strategies for in vitro seizure liability assessment
Tukker, A. M., & Westerink, R. H. S. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1876026 · Cited by 27
Application Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 30
Utility‐based optimization of phase II/III programs
Kirchner, M., Kieser, M., Götte, H., et al. (2015) · Statistics in Medicine · doi:10.1002/sim.6624 · Cited by 25
Putting translational science on to a global stage
Gilliland, C. T., Zuk, D., Kočiš, P., Johnson, M. S., Hay, S., Hajdúch, M., Biétrix, F., Aversa, G., Austin, C. P., & Ussi, A. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.33 · Cited by 25
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
Carugo, A., & Draetta, G. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055645 · Cited by 25
Advances in microfluidic 3D cell culture for preclinical drug development
(2022) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.07.022 · Cited by 23
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol
Espinasse, A., Solovyeva, O., Dimairo, M., Weir, C. J., Jaki, T., Mander, A., Kightley, A., Evans, J., Lee, S., Bedding, A. W., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068173 · Cited by 21
Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
Jerome, R. N., Joly, M. M., Kennedy, N., Shirey-Rice, J. K., Roden, D. M., Bernard, G. R., Holroyd, K. J., Denny, J. C., & Pulley, J. M. (2020) · Drug Safety · doi:10.1007/s40264-020-00915-6 · Cited by 24
Drug-Induced Seizures: Considerations for Underlying Molecular Mechanisms
Larson, E. A., Accardi, M. V., Zhong, Y., Paquette, D., & Authier, S. (2021) · International Journal of Toxicology · doi:10.1177/10915818211040483 · Cited by 24
“Drug-induced seizure (DIS) is a relatively well characterized adverse effect which can be observed in non-clinical studies but also in the clinical setting.(1,10) DIS are seizures precipitated by the pharmacological and/or toxicological effects of a given chemical entity following acute or chronic exposure or withdraw…”
Background
Cell Culture Model Evolution and Its Impact on Improving Therapy Efficiency in Lung Cancer
Roman, V., Mihaila, M. A., Radu, N., Marineata, S., Diaconu, C. C., & Bostan, M. (2023) · Cancers · doi:10.3390/cancers15204996 · Cited by 26
“…the emergence and development of new research models such as spheroids, organoid, or microﬂuidic platforms that mimic the existing in vivo conditions have contributed to the reduction of the number of animals used in the laboratory or to the replacement of animal studies where possible [37,38].”
Background
Joining Forces: The Chemical Biology–Medicinal Chemistry Continuum
Plowright, A. T., Ottmann, C., Arkin, M. R., Auberson, Y. P., Timmerman, H., & Waldmann, H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.019 · Cited by 25
Use of Mendelian Randomization for Identifying Risk Factors for Brain Tumors
Howell, A., Zheng, J., Haycock, P., McAleenan, A., Relton, C. L., Martin, R. M., & Kurian, K. M. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00525 · Cited by 26
“A quarter of the drugs that enter clinical development fail due to their ineffectiveness (Ashburn and Thor, 2004; Arrowsmith and Miller, 2013).”
Background
Human genetics as a model for target validation: finding new therapies for diabetes
Thomsen, S. K., & Gloyn, A. L. (2017) · Diabetologia · doi:10.1007/s00125-017-4270-y · Cited by 24
“The most common reasons for failure include lack of efficacy and/or unsuitable safety profiles, even in cases where the correct target is engaged [4, 5].”
Background
All‐in‐one microfluidic design to integrate vascularized tumor spheroid into high‐throughput platform
Kim, Y., Ko, J., Shin, N., Park, S., Lee, B., Kim, S., Song, J., Lee, S.-J., Kang, K., Lee, J., et al. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28221 · Cited by 24
“There are cases where unexpected side effects that are not filtered out during the bench side or preclinical process appear or the efficacy in the body is drastically reduced (Ahn et al., 2018; Arrowsmith & Miller, 2013; Heylman et al., 2014; Smietana et al., 2016).”
Background
Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway–tumour–stroma lung cancer model
Mas, C., Boda, B., Caul-Futy, M., Huang, S., Wiszniewski, L., & Constant, S. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.012 · Cited by 24
Preclinical progenitor cell therapy in traumatic brain injury: a meta-analysis
Jackson, M. L., Srivastava, A. K., & Cox, C. S. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.02.078 · Cited by 23
The value of organs-on-chip for regulatory safety assessment
Heringa, M. B. (2019) · ALTEX · doi:10.14573/altex.1910111 · Cited by 27
“However, over the last decades it has become increasingly apparent that animal studies may have limited predictive value for various toxic effects in humans (e.g., Adler et al., 2011; Arrowsmith and Miller, 2013).”
Background
Flexible Drug Approval Policies
Bravo, F., Corcoran, T., & Long, E. F. (2021) · Manufacturing & Service Operations Management · doi:10.1287/msom.2020.0963 · Cited by 23
The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
“Surveys have suggested that more than half of these drug candidates fail in Phases II and III because of a lack of efficacy, and another third of failures are attributed to safety issues [3,4].”
Background
Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry
Munson, M., Lieberman, H., Tserlin, E., Rocnik, J. L., Ge, J., Fitzgerald, M., Patel, V. F., & Garcı́a-Echeverrı́a, C. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.010 · Cited by 22
Predictivity of in vitro non-clinical cardiac contractility assays for inotropic effects in humans — A literature search
Wallis, R., Gharanei, M., & Maddock, H. L. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.05.009 · Cited by 22
Progression-seeking bias and rational optimism in research and development
Lendrem, D. W., Lendrem, C., Peck, R., Senn, S. J., Day, S. J., & Isaacs, J. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4320-c1 · Cited by 21
How drugs are discovered and developed
Collis, M. G. (2013) · Physiology News · doi:10.36866/pn.92.23 · Cited by 21
Organ‐On‐A‐Chip Devices: Technology Progress and Challenges
Obeid, P. J., Yammine, P., El‐Nakat, H., Kassab, R., Tannous, T., Nasr, Z., Maarawi, T., Dahdah, N., Safadi, A. E., Mansour, A., et al. (2024) · ChemBioChem · doi:10.1002/cbic.202400580 · Cited by 28
Estimation of Drug-Target Residence Time by Targeted Molecular Dynamics Simulations
Ziada, S., Diharce, J., Raimbaud, E., et al. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00852 · Cited by 21
Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood–brain barrier
Bellwon, P., Culot, M., Wilmes, A., Schmidt, T., Zurich, M., Schultz, L., Schmal, O., Gramowski, A., Weiss, D. G., Jennings, P., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.01.003 · Cited by 27
R&D productivity rides again?
Lendrem, D. W., Senn, S. J., Lendrem, C., & Isaacs, J. D. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1653 · Cited by 21
“However, these rising costs may be attributable, at least in part, to an increase late-stage attrition costs arising from historical changes to the drug development process [13–16].”
Background
Unlocking the potential of established products: toward new incentives rewarding innovation in Europe
Nayroles, G., Frybourg, S., Gabriel, S., Kornfeld, A., Antoñanzas, F., Espín, J., Jommi, C., Martini, N., de Pouvourville, G., Tolley, K. H., et al. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1298190 · Cited by 23
“[36] Additionally, as safety accounts for almost 30% of drug failures in clinical trials,[37] EPs – for which large amounts of valuable real-life data on safety are available – should be considered as an interesting option to invest in.”
Background
Druggability of Coronary Artery Disease Risk Loci
Tragante, V., Hemerich, D., Alshabeeb, M. A., Brænne, I., Lempiäinen, H., Patel, R. S., den Ruijter, H. M., Barnes, M. R., Moore, J. H., Schunkert, H., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.001977 · Cited by 22
Investigation of machine learning techniques on proteomics: A comprehensive survey
Sonsare, P. M., & Gunavathi, C. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.09.004 · Cited by 23
Better Science with Human Cell-based Organ and Tissue Models
Heinonen, T. (2015) · Alternatives to Laboratory Animals · doi:10.1177/026119291504300107 · Cited by 21
“Some European legislation, such as REACH (4) and the biocidal product regulation (18), specify preferred test species (e.”
Background
Connecting genetics and gene expression data for target prioritisation and drug repositioning
Ferrero, E., & Agarwal, P. (2018) · BioData Mining · doi:10.1186/s13040-018-0171-y · Cited by 18
Endocannabinoids increase human adipose stem cell differentiation and growth factor secretion in vitro
Ruhl, T., Schneider, P., Kim, B., & Beier, J. P. (2020) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3152 · Cited by 20
“When translating ASCs into clinical practice, the still missing precise comprehension of the ASC biology is one reason for high attrition rates (Arrowsmith & Miller, 2013).”
Background
Bone microphysiological models for biomedical research
Verdugo-Avello, F., Wychowaniec, J. K., Villacis-Aguirre, C. A., D’Este, M., & Toledo, J. R. (2025) · Lab on a Chip · doi:10.1039/d4lc00762j · Cited by 24
Unraveling liver complexity from molecular to organ level: Challenges and perspectives
D'Alessandro, L. A., Hoehme, S., HENNEY, A. M., Drasdo, D., & Klingmüller, U. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.11.005 · Cited by 21
“…approaches and the many studies undertaken, evidence of practical value of these approaches has been frustratingly limited (Henney, 2012) and industry still sees major late stage failures due to lack of efficacy and safety (Arrowsmith and Miller, 2013; Henney and Superti-Furga, 2008; Henney, 2009).”
Background
The fruit fly Drosophila melanogaster as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy
Wang, Y., Moussian, B., Schaeffeler, E., Schwab, M. G., & Nies, A. T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.002 · Cited by 17
Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites
Hughes, T. B., Dang, N. L., Kumar, A., Flynn, N. R., & Swamidass, S. J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00360 · Cited by 18
“3 Furthermore, idiosyncratic adverse drug reactions (IADRs) frequently only arise after approval, incurring significant resources.”
Background
The Rare Diseases Clinical Research Network: a model for clinical trial readiness
Lumsden, J. M., & Urv, T. K. (2023) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040231219272 · Cited by 22
In Silico Predictions of Drug – Drug Interactions Caused by CYP1A2, 2C9 and 3A4 Inhibition – a Comparative Study of Virtual Screening Performance
Kaserer, T., Höferl, M., Müller, K., Elmer, S., Ganzera, M., Jäger, W. R., & Schuster, D. (2015) · Molecular Informatics · doi:10.1002/minf.201400192 · Cited by 19
One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
Chai, C. L. L., & Mátyus, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.167 · Cited by 20
NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies
Venook, A. P., Arcila, M. E., Benson, A. B., Berry, D. A., Camidge, D. R., Carlson, R. W., Choueiri, T. K., Guild, V., Kalemkerian, G. P., Kurzrock, R., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0161 · Cited by 20
From Reproducibility to Translation in Neurodegenerative Disease
Zeiss, C. J. (2017) · ILAR Journal · doi:10.1093/ilar/ilx006 · Cited by 18
MitoToxy assay: A novel cell-based method for the assessment of metabolic toxicity in a multiwell plate format using a lactate FRET nanosensor, Laconic
Contreras‐Baeza, Y., Ceballo, S., Arce‐Molina, R., Sandoval, P. Y., Alegría, K., Barros, L. F., & Martín, A. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224527 · Cited by 19
Rectifying Cancer Drug Discovery Through Network Pharmacology
Azmi, A. S., & Mohammad, R. M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.6 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 19
“In the clinic, the majority of drug candidates between phase II and submission will fail because of lack of efficacy (56% between 2011 and 2012) or safety (28% in the same time period, including failures due to an insufficient therapeutic index).(9) The impact of this attrition is evident in recent analyses modeling t…”
Background
Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer
Chiu, W.-C., Ou, D., & Tan, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169195 · Cited by 18
A novel approach for establishing cardiovascular drug efficacy
Heerspink, H. J. L., Grobbee, D. E., & de Zeeuw, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090-c2 · Cited by 18
Parkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
Toxicological findings about an anticancer fraction with casearins described by traditional and alternative techniques as support to the Brazilian Unified Health System (SUS)
Ferreira, P. M. P., Santos, D. B., Silva, J. D. N., Goudinho, A. F., Ramos, C. L. S., de Souza, P. C., Almeida, R. S., Moura, D. S., Oliveira, R., Grisólia, C. K., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112004 · Cited by 18
Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective
Liu, C., Xia, L., Fu, K., Cao, X., Yan, W., Cheng, J., Roux, T., Peletier, L. A., Yin, X., & Guo, D. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173157 · Cited by 21
Construction of in vitro patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy
Takahashi, N., Higa, A., Hiyama, G., Tamura, H., Hoshi, H., Dobashi, Y., Katahira, K., Ishihara, H., Takagi, K., Goda, K., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12667 · Cited by 17
Renal Safety Pharmacology in Drug Discovery and Development
Benjamin, A., da Costa, A. N., Delaunois, A. G., Rosseels, M.-L. A., & Valentin, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_13 · Cited by 20
Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
Walker, L. C., & Lawrence, A. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1502269 · Cited by 19
Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer
Espedal, H., Berg, H. F., Fonnes, T., Fasmer, K. E., Krakstad, C., & Haldorsen, I. S. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03086-9 · Cited by 17

Authors: Arrowsmith, J., & Miller, P.
Affiliations: Thomson Reuters (United Kingdom) (GB)
Corresponding author: Miller, Philip
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2013-08
Volume: 12
Issue: 8
Pages: 569-569
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd4090
OpenAlex: W1968779484
Cited by: 697
References: 0
Citations by year: 2026: 42 · 2025: 35 · 2024: 45 · 2023: 48 · 2022: 38 · 2021: 55 · 2020: 51 · 2019: 59 · 2018: 57 · 2017: 61 · 2016: 74 · 2015: 63 · 2014: 39 · 2013: 30
Type: other
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords: attrition rates, drug development, clinical trial failure, drug discovery pipeline
MeSH terms: Humans, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Early Termination of Clinical Trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase II and Phase III attrition rates 2011–2012

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks